Showing results (21-30 of 148) with videos related to

Sort By:
Pageof 15
BMC Pulmonary Medicine|August 27, 2013
Chronic obstructive pulmonary disease and exacerbations: patient insights from the global Hidden Depths of COPD surveyNeil Barnes, Peter M A Calverley, Alan Kaplan, et al.
The Practitioner|December 21, 2010
Opportunistic case finding pivotal in diagnosing COPDPaul P Walker
American Journal of Respiratory and Critical Care Medicine|July 14, 2023
A Double-Blind, Randomized, Placebo-controlled Trial of Long-Term Doxycycline Therapy on Exacerbation Rate in Patients with Stable Chronic Obstructive Pulmonary DiseaseJames P Allinson, Ben H Vlies, Simon E Brill, et al.
Respiratory Medicine|August 12, 2008
Identifying COPD patients at increased risk of mortality: predictive value of clinical study baseline dataDavid M G Halpin, Stefan Peterson, Thomas P Larsson, et al.
Annals of the American Thoracic Society|September 29, 2017
The Effect of Defining Chronic Obstructive Pulmonary Disease by the Lower Limit of Normal of FEV1/FVC Ratio in Tiotropium Safety and Performance in Respimat ParticipantsPeter M A Calverley, Achim Mueller, Andrew Fowler, et al.
Advances in Therapy|April 17, 2016
Tiotropium Respimat(®) Versus HandiHaler(®): Comparison of Bronchodilator Efficacy of Various Doses in Clinical TrialsPeter M A Calverley, Michael Könen-Bergmann, Frank Richard, et al.
Chest|October 14, 2003
Withdrawal from treatment as an outcome in the ISOLDE study of COPDPeter M A Calverley, Sally Spencer, Lisa Willits, et al.
Respiratory Medicine|February 2, 2019
Impact of smoking status and concomitant medications on the effect of high-dose N-acetylcysteine on chronic obstructive pulmonary disease exacerbations: A post-hoc analysis of the PANTHEON studyAlberto Papi, Jinping Zheng, Gerard J Criner, et al.
COPD|December 2, 2006
Development of a population-based screening questionnaire for COPDPeter M A Calverley, Robert J Nordyke, R J Halbert, et al.
Respiratory Research|January 29, 2011
Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPDStephen I Rennard, Peter M A Calverley, Udo M Goehring, et al.
Pageof 15